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Abstract 
Background: Atrial fibrillation is a progressive arrhythmia, the exact mechanism underlying the progressive nature of 
recurrent AF episodes is still unknown. Recently, it was found that key players of the protein quality control system of 
the cardiomyocyte, i.e. Heat Shock Proteins, protect against atrial fibrillation progression by attenuating atrial electrical 
and structural remodeling (electropathology). HALT & REVERSE aims to investigate the correlation between electropa-
thology, as defined by endo- or epicardial mapping, Heat Shock Protein levels and development or recurrence of atrial 
fibrillation following pulmonary vein isolation, or electrical cardioversion or cardiothoracic surgery.
Study design: This study is a prospective observational study. Three separate study groups are defined: (1) cardiotho-
racic surgery, (2) pulmonary vein isolation and (3) electrical cardioversion. An intra-operative high-resolution epicar-
dial (group 1) or endocardial (group 2) mapping procedure of the atria is performed to study atrial electropathology. 
Blood samples for Heat Shock Protein determination are obtained at baseline and during the follow-up period at 
3 months (group 2), 6 months (groups 1 and 2) and 1 year (group 1 and 2). Tissue samples of the right and left atrial 
appendages in patients in group 1 are analysed for Heat Shock Protein levels and for tissue characteristics. Early post 
procedural atrial fibrillation is detected by continuous rhythm monitoring, whereas late post procedural atrial fibrilla-
tion is documented by either electrocardiogram or 24-h Holter registration.
Conclusion: HALT & REVERSE aims to identify the correlation between Heat Shock Protein levels and degree of 
electropathology. The study outcome will contribute to novel diagnostic tools for the early recognition of clinical atrial 
fibrillation.
Trial Registrations: Rotterdam Medical Ethical Committee MEC-2014-393, Dutch Trial Registration NTR4658
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Background
Atrial fibrillation (AF) initially presents with short, 
self-terminating episodes and progresses into long-
lasting episodes which are unlikely to convert spon-
taneously to sinus rhythm [1]. The exact mechanism 
underlying this progression is unknown. At present, there 
are no diagnostic tests or biomarkers available predicting 
recurrences of progressive AF episodes. In daily clinical 
practice, we can for example, not predict which patients 
develop AF following cardiac surgery or AF recurrences 
after pulmonary vein isolation (PVI) or electrical cardio-
version (ECV).
AF persistence induces atrial remodeling on an elec-
trical, structural and contractile level, also referred to as 
electropathology [2]. Electrical changes such as shorten-
ing of AF cycle length and contractile dysfunction occur 
within days after AF onset [3, 4]. After weeks of AF per-
sistence, structural alterations become manifest in the 
extracellular matrix and in cardiomyocytes [1, 5–7]. 
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Electrical and contractile abnormalities are completely 
reversible within weeks or days after restoration of sinus 
rhythm [3, 7–10], whereas recovery from structural 
remodeling is slow and takes up to months [11]. This 
finding indicates that structural remodeling underlies 
AF progression and recurrences. Therefore, research is 
directed at identifying key pathways involved in struc-
tural remodeling.
Recently it was demonstrated that derailment of car-
diomyocyte proteostasis, underlies AF progression and 
recurrences [12–15]. Cells, including cardiomyocytes, 
depend for proper functioning on the maintenance of 
proteostasis: the balance in protein synthesis, folding, 
assembling, trafficking, and clearance [16, 17] (Fig.  1). 
Chaperones, mainly consisting of Heat Shock Proteins 
(HSPs), assist in the maintenance of proteostasis [17–
19]. Upon acute stress e.g. in paroxysmal AF, HSPs are 
upregulated [20]. The progressive nature of AF lies in the 
gradual, often age-related, exhaustion of the HSP levels 
and subsequent derailment of proteostasis, resulting in 
structural remodeling and contractile dysfunction of car-
diomyocytes (Fig.  2). Therefore, compounds that boost 
HSP expression, such as geranylgeranylacetone (GGA) 
and GGA derivatives [21, 22], are of clinical interest. 
Indeed, HSPs boosting, via Heat Shock Factor-1 activa-
tion, protected against derailment of proteostasis and AF 
progression and recurrences in several experimental AF 
models, including tachypaced cardiomyocytes [23], Dros-
ophilas [15] and canine models [24].
The HALT & REVERSE (Hsf1 Activators Lower Cardio-
myocyt damage: Towards a novel approach to REVERSE 
atrial fibrillation, MEC 2014-393, NTR 4658) project 
focusses on the correlation between HSPs and progres-
sion of electropathology [2]. Hereto, the HSP levels 
in blood and atrial tissue samples are determined and 
related to electrophysiological characteristics of the atria 
obtained from epicardial mapping during cardiothoracic 
surgery and endovascular mapping during PVI. The find-
ings will elucidate whether HSP levels and electrophysi-
ological characteristics represent a novel diagnostic tool 
Fig. 1 Proteostasis is the balance between protein expression, folding, function and clearance in the cell. When proteins are generated at the 
ribosomes after translation, chaperones, such as heat shock proteins, guide proper protein folding, and when not folded correctly, they guide 
remodeling of the protein. Furthermore, these chaperones have a role in limiting protein aggregation and they have a role in protein degradation
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(a so-called “bio-electrical fingerprint”) to predict the 
clinical outcome for AF patients and/or cardiac surgery.
Study design
HALT & REVERSE is a prospective observational study, 
with a planned duration of 48 months. This study is car-
ried out according to the principals of the Declaration 
of Helsinki Version and in accordance with the Medical 
Research involving Human Subjects Act. The study is 
approved by the Rotterdam local medical ethical com-
mittee (MEC 2014-393).
Study objectives
The primary study objectives are to test the correlation 
between atrial electropathology as visualised by high-res-
olution epicardial mapping or endovascular mapping, HSP 
levels, atrial tissue characteristics and clinical characteris-
tics in patients undergoing either open chest cardiac sur-
gery, PVI or ECV. Secondly, the correlation between HSP 
levels and development or recurrence of AF in patients 
undergoing cardiothoracic surgery, PVI or ECV is tested.
Study population
For the HALT & REVERSE project, three separate study 
groups are defined, consisting of patients scheduled 
for (1) cardiothoracic surgery, (2) PVI and (3) ECV for 
symptomatic AF. Each group contains 100 consecutive 
patients. Patients are recruited at the Department of Car-
diothoracic Surgery or at the Department of Cardiology 
at the Erasmus Medical Center, Rotterdam, The Neth-
erlands. Prior to enrolling in the study, each patient is 
provided an oral and a written explanation of the study 
procedure. Written informed consent is obtained from 
all patients.
Blood samples for baseline HSP level determination 
taken from all patients prior to the scheduled interven-
tion (surgery, PVI or ECV) (Fig. 3). Patient characteristics 
(e.g. age, medical history, cardiovascular risk factors) are 
obtained from the patient’s file.
Inclusion criteria
In order to be eligible to participate in this study, all sub-
jects must be >18 years old. In the cardiothoracic surgery 
group, only patients scheduled for elective cardiothoracic 
surgery for structural heart disease with or without a his-
tory of AF are included.
The PVI group will enrol patients with paroxysmal or 
(long-standing) persistent AF. The ECV group will con-
sist of patients with symptomatic, AF presenting for elec-
trical cardioversion.
Exclusion criteria
A potential subject who meets any of the following cri-
teria in all three study groups are excluded from partici-
pation in this study: paced atrial rhythm, haemodynamic 
instability, presence of cardiac assist devices, usage of 
Fig. 2 Concept of the HALT & REVERSE project. In the normal heart 
Protein Quality Control (PQC) and the Heat Shock Response (HSR, 
upper panel: green area) maintain proteostasis in times of stress. 
However, with the duration of AF and with increasing age, the heat 
shock protein (HSP) levels get exhausted. This leads to a derailment of 
proteostasis (upper panel: red area), resulting in structural remodeling 
and contractile dysfunction of cardiomyocytes, because of, amongst 
others, degradation of sarcomers (myolysis, left and right lower panel). 
AF progresses in time (upper panel: solid line), which is rooted in the 
underlying electropathology. By pharmacological boosting of HSPs, 
we aim to HALT or even REVERSE atrial electropathology and conse-
quently AF progression (upper panel: dashed line)
Fig. 3 Timecourse of the HALT & REVERSE project. A baseline blood 
sample (red bar) is obtained from all patients 1 day prior to the pro-
cedure. In the pulmonary vein isolation—and cardiac surgery group, 
the study procedure (black bar epicardial or endocardial mapping 
procedure) is performed during the elective therapeutic interven-
tion (yellow bar) and post-procedural continuous rhythm monitoring 
afterwards (green bars). The blue bars indicate long term follow-up 
(>3 months) including a visit to the outpatient clinic with electrocar-
diography, blood samples and 24-h Holter recordings when indicated
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inotropic agents prior to intervention or patients under-
going emergency or redo cardiac surgery.
Sample size calculation
Approximately 25  % of patients undergoing cardiotho-
racic surgery develop early postoperative AF [25]. Esti-
mated AF recurrence rate 1 year after PVI is 45 % as has 
been shown in previous studies [26–28], whereas the 
arrhythmia tends to recur within 1 year in 25–40 % [29–
31] after ECV.
For none of our study groups, data testing the correla-
tion between HSP and AF development or recurrence (in 
humans) is available. Therefore, a reliable parameter for 
sample size calculation is not available. Based upon the 
data mentioned above, we expect a pilot study with 100 
patients in each group to be suitable for further determi-
nation of the exact number of patients needed to gener-
ate a power of 0.95 with a significance of 0.05.
Intra‑operative mapping procedure
High-resolution epicardial mapping of the entire atria 
according to a previously described mapping scheme is 
performed during open chest cardiac surgery [32]. A ref-
erence electrode is temporarily attached to the right atrial 
appendage. An indifferent electrode consists of a steel 
wire, placed in subcutaneous tissue. The mapping pro-
cedure will be performed using a custom made 192-site 
electrode array [32] with a 2 mm inter-electrode distance. 
Recordings are made at nine consecutive sites following a 
predefined mapping scheme (Fig. 4) during sinus rhythm 
(5  s/site), during pacing maneuvers for inducing AF (1 
site, Bachman’s Bundle), and during AF (10  s/site). Pac-
ing maneuvers will be performed with epicardial atrial 
fixed rate pacing at 250–300–350 beats per minute suc-
cessively, using a standard temporary pacemaker device. 
If AF sustains until the end of the mapping procedure, 
sinus rhythm will be restored with 5–10 Joule synchro-
nous electric cardioversion.
After introduction cannulas of the cardiopulmonary 
bypass into the right atrium via the right atrial appendage 
(RAA) a tissue sample is obtained from the incision site 
in all patients. A tissue sample of the left atrial append-
age (LAA) is obtained if the LAA is incised or amputated 
during surgery. All collected tissue samples are immedi-
ately snap-frozen in liquid nitrogen and stored at −80 °C.
After the surgical procedure, heart rhythm is con-
tinuously monitored until hospital discharge in order to 
detect early post-operative AF (PoAF). PoAF is defined 
as a complete irregular heartbeat without consistent 
P waves, sustaining for at least 30  s. At 6  months and 
1  year after the procedure, patients visit the outpatient 
clinic for detection of late post-operative AF. A 12-lead 
electrocardiogram and a blood sample for HSP analysis 
are obtained. A 24-h Holter registration is performed 
when AF is suspected.
Pulmonary vein isolation
An endovascular mapping procedure is performed prior 
to isolation of the pulmonary veins. Atrial electropathol-
ogy is studied by means of programmed electrical stimu-
lation in the right and the left atrium, including fixed rate 
atrial pacing, delivery of atrial extra systoles and decre-
mental pacing maneuvers. Recordings of the right atrium 
are made by a decapolar catheter at the right atrial free 
wall and pacing is performed from the ablation cathe-
ter, which is positioned in the RAA. Mapping in the left 
atrium is performed by placing a Lasso catheter at the 
posterior wall and a decapolar catheter in the coronary 
sinus, while pacing from the left atrial roofline. Subse-
quently, the PVI is performed according to the electro-
physiologist’ choice by either radiofrequency ablation or 
cryoballoon ablation.
According to standard care, heart rhythm is monitored 
continuously until discharge. Recordings are analyzed to 
detect early AF episodes, sustained for at least 30  s. At 
3, 6 months and 1 year after the procedure, patients visit 
the outpatient clinic. During these visits, 12-lead ECGs 
and 24-h Holter registrations are performed to detect late 
post procedural AF recurrences and an additional blood 
sample is obtained for HSP level determination.
Fig. 4 Epicardial mapping scheme. 1 Left superior pulmonary vein; 2 
right superior pulmonary vein; 3 left inferior pulmonary vein; 4 right 
inferior pulmonary vein; 5 inferior caval vein; 6 superior caval vein; 7 
coronary sinus. The left and right atrium and Bachmann’s Bundle are 
mapped following a predefined epicardial mapping scheme along 
anatomical structures, by the use of an 192 polar electrode array 
(green)
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Electrical cardioversion
Patients will be interviewed by telephone at 6 and 
12 months to detect AF recurrences.
Tissue analysis
All obtained blood samples and atrial tissue samples are 
stored at −80  °C until analysis. All samples are tested 
for HSP biomarkers, including HSP70 and HSP27. Bio-
marker levels are determined by commercially available 
ELISA’s and Western blot analysis.
Main study parameters
Intra‑operative mapping
Custom-made software used for off-line analysis of the 
recordings have previously been described in detail 
[32–34]. Local activation times of the unipolar atrial 
potentials are automatically detected in order to recon-
struct color-coded activation-, conduction block-, 
breakthrough-, voltage- and wavemaps during sinus 
rhythm and AF [32–34]. An example of an activation and 
wavemap constructed during AF is given in Fig.  5. The 
maps are used to quantify electrophysiological variables. 
These variables are correlated with the pre-operative HSP 
level and development of post-operative AF.
Pulmonary vein isolation
The degree of fractionated electrograms obtained from 
multiple sites in the right and left atrium are studied for 
fractionation and cycle length variation. HSP levels prior to 
PVI are correlated with the development of AF recurrence.
Electrical cardioversion
Correlation between HSP levels prior to cardioversion 
and successful restoration of sinus rhythm and AF recur-
rences is determined.
Study endpoints
For all groups, endpoint of the study is reached when 
AF develops after cardiac surgery or recurs after ECV or 
PVI. The correlation between several biomarkers (HSP70, 
HSP27) and development or recurrences of AF is deter-
mined, but also the correlation between degree of elec-
tropathology and development or recurrences of AF. The 
relationship between atrial electrophysiological variables, 
as visualised by epicardial mapping, and structural tis-
sue characteristics are tested. The findings will indicate 
whether HSP levels and/or the degree of electropathol-
ogy represent a novel diagnostic tool to predict the clini-
cal outcome of AF progression and/or recurrences.
Statistical analysis
The association between biomarker levels and devel-
opment or recurrence of atrial fibrillation is calculated 
using multivariate logistic regression (for short term 
outcome) and cox regression models (for long-term out-
come). Furthermore, Kaplan–Meier life tables are created 
for the three groups (cardiac surgery, PVI and ECV) and 
Log rank tests are used to compare the different groups.
ANOVA is utilized to compare various electrophysio-
logical continuous parameters, for categorical parameters 
the Chi-square test will be used. Repeated HSP measure-
ments are conducted by Joint modeling and mixed mod-
eling analysis. Multiple biomarkers levels are corrected 
by ANOVA with Bonferoni adjustments.
Fig. 5 Epicardial high-resolution mapping of the atria. Atrial 
electrograms recorded during sinus rhythm (SR), atrial pacing (P) 
and (electrically induced) atrial fibrillation (AF) obtained during the 
epicardial mapping procedure are shown in the upper panel. The left 
lower panel shows an example of an activation map during electri-
cally induced AF of the right atrium in a patient undergoing coronary 
artery bypass grafting without a history of AF. Isochrones are drawn at 
5 ms, areas of conduction block are indicated by black bars, the origin 
of peripheral and epicardial breakthrough waves by respectively grey 
dots and white asterisks. The arrows indicate main activation direction. 
Corresponding wavemap is displayed in the right lower panel. The 
wavemap shows the different types of fibrillation waves entering 
the mapping area from various directions. These maps are used to 
determine the incidence of e.g. conduction block and epicardial 
breakthrough
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Conclusion
HALT & REVERSE aims to examine the interplay 
between electropathological substrate underlying AF, 
and HSP levels in the blood and atrial tissue, in order to 
predict development, recurrence or progression of AF. 
The results will elucidate whether HSP levels and electro-
physiological characteristics can be used as a future diag-
nostic tool in the clinical setting.
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